Skip to main content

IDEXX Laboratories, Inc. (IDXX) Stock

IDEXX Laboratories, Inc. Stock Details, Movements and Public Alerts

Stock Details

IDEXX Laboratories, Inc. (IDXX), a prominent company in the healthcare sector within the diagnostics & research industry, is based in United States and primarily trades on the NMS.Currently, the stock is trading at $559.51. Over the past 52 weeks, it has ranged between $518.55 and $769.98. This places the current price at 72.7% of its 52-week high and 7.9% above its 52-week low. Recent trading volume was recorded at 388,926. The 14-day Relative Strength Index (RSI) stands at 48.54, suggesting neutral conditions. The stock is currently trading below its 50-day moving average of $560.03 by 0.09%. Similarly, it is below its 200-day moving average of $614.29 by 8.92%. The MACD histogram is -2.58, indicating bearish momentum (MACD Line: -1.89, Signal Line: 0.70). The International Securities Identification Number (ISIN) for this stock is US45168D1046. There is currently 1 active alert set for IDXX by users.

52-Week Range

$769.98 - $518.55

-27.33% from high · +7.90% from low

Avg Daily Volume

638,360

20-day average

100-day avg: 626,175

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

39.07

Above market average

Forward P/E

33.42

Earnings expected to grow

PEG Ratio

3.41

Potentially overvalued

Price to Book

27.37

EV/EBITDA

27.73

EPS (TTM)

$14.32

Price to Sales

9.68

Beta

1.54

More volatile than market

Q:How is IDXX valued relative to its earnings and growth?
IDEXX Laboratories, Inc. trades at a P/E ratio of 39.07, which is above the market average of approximately 20. This premium valuation suggests investors expect above-average growth or the company has competitive advantages justifying the higher multiple. Looking ahead, the forward P/E of 33.42 is lower than the current P/E, indicating analysts expect earnings to grow over the next year. The PEG ratio of 3.41 indicates a premium valuation even accounting for growth.
Q:What is IDXX's risk profile compared to the market?
With a beta of 1.54, IDEXX Laboratories, Inc. is significantly more volatile than the market. For every 10% market move, this stock tends to move 15% in the same direction. Higher beta stocks offer greater potential returns but with increased risk. The price-to-book ratio of 27.37 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

25.03%

Operating Margin

34.98%

EBITDA

$1.62B

Return on Equity

74.21%

Return on Assets

27.08%

Revenue Growth (YoY)

9.70%

Earnings Growth (YoY)

17.60%

Q:How profitable and efficient is IDXX's business model?
IDEXX Laboratories, Inc. achieves a profit margin of 25.03%, meaning it retains $25.03 from every $100 in revenue after all expenses. This is an impressive margin, indicating strong pricing power and efficient cost management that allows the company to generate substantial profits. The operating margin of 34.98% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 74.21% and ROA at 27.08%, the company generates strong returns on invested capital.
Q:What are IDXX's recent growth trends?
IDEXX Laboratories, Inc.'s revenue grew by 9.70% year-over-year, showing steady progress in growing the business. This positive trajectory indicates the company maintains competitive positioning in its markets. Earnings increased by 17.60% year-over-year, outpacing revenue growth through improved margins. These growth metrics should be evaluated against Diagnostics & Research industry averages for proper context.

Company Size & Market

Market Cap

$44.1B

Revenue (TTM)

$4.55B

Revenue/Share (TTM)

$57.17

Shares Outstanding

78.78M

Book Value/Share

$20.45

Asset Type

EQUITY

Q:What is IDXX's market capitalization and position?
IDEXX Laboratories, Inc. has a market capitalization of $44.1B, classifying it as a large-cap stock ($10B-$200B). Large-caps are typically industry leaders with established business models, offering a balance of stability and growth potential. They often provide dividend income and are core holdings in institutional portfolios. With 78.78M shares outstanding, the company's ownership is relatively concentrated. As a participant in the Diagnostics & Research industry, it competes with other firms in this sector.
Q:How does IDXX's price compare to its book value?
IDEXX Laboratories, Inc.'s book value per share is $20.45, while the current stock price is $559.51, resulting in a price-to-book (P/B) ratio of 27.37. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As EQUITY, this represents a specific type of security.

Analyst Ratings

Analyst Target Price

$698.92

24.92% upside potential

Analyst Recommendations

Strong Buy

4

Buy

5

Hold

5

Sell

1

Strong Sell

0

Q:How reliable are analyst predictions for IDXX?
15 analysts cover IDXX with 60% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The mixed views reflect uncertainty about the outlook. The consensus target of $698.92 implies 24.9% upside, but targets are often adjusted to follow price moves rather than predict them.
Q:What is the Wall Street consensus on IDXX?
Current analyst recommendations:4 Strong Buy, 5 Buy, 5 Hold, 1 Sell, 0The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Aug 25, 2026, 02:28 AM

Technical Indicators

RSI (14-day)

48.54

Neutral

50-Day Moving Average

$560.03

-0.09% below MA-50

200-Day Moving Average

$614.29

-8.92% below MA-200

MACD Line

-1.89

MACD Signal

0.70

MACD Histogram

-2.58

Bearish

Q:What does IDXX's RSI value tell investors?
The RSI (Relative Strength Index) for IDXX is currently 48.54, indicating the stock is in neutral territory (40-60 range). Neither buyers nor sellers have clear control, suggesting consolidation or balanced market forces. Combined with the price being below the 50-day moving average, this confirms bearish conditions.
Q:How should traders interpret IDXX's MACD and moving average crossovers?
MACD analysis shows the MACD line at -1.89 below the signal line at 0.70, with histogram at -2.58. This bearish crossover indicates downward pressure. The wide histogram confirms strong momentum. The 50-day MA ($560.03) is below the 200-day MA ($614.29), forming a death cross pattern that often warns of extended weakness. Price is currently below both MAs, confirming weakness.

Indicators last updated: Aug 25, 2026, 12:53 AM

Active Alerts

Alert Condition
Price decreases by
Threshold
20%
Created
Apr 28, 2026, 07:45 PM

Stay Ahead of the Market with IDEXX Laboratories, Inc. Alerts

Set up price alerts for IDEXX Laboratories, Inc. and get notified instantly when the price hits your target. Never miss an important price movement again.